Key result
Moderately elevated carboxyhemoglobin (>2%) in patients with acute ischemic heart disease significantly increased the need for early antiarrhythmic treatment (p=0.003).
Why the study?
Do moderately elevated levels of carboxyhemoglobin (>2%) aggravate the early clinical course in patients with acute ischemic heart disease?
Population
66 patients with acute ischemic heart disease
Comparison
Moderately elevated levels of carboxyhemoglobin vs Carboxyhemoglobin levels ≤ 2%
Design
Cohort
Follow-up
early course (including first 6 hours after admission)
Authors
Loading...
May warrant targeted monitoring in acute ischemic heart disease; leaves open causal confirmation and practice change.
Cohort (n=66)
Do moderately elevated levels of carboxyhemoglobin (>2%) aggravate the early clinical course in patients with acute ischemic heart disease?
p-value: p=0.003
Moderately elevated carboxyhemoglobin (>2%) in acute ischemic heart disease is associated with higher CPK levels in transmural infarction and an increased early need for antiarrhythmic therapy, suggesting it actively aggravates the disease course.
Mall et al. (2009) conducted a cohort in acute ischemic heart disease (n=66). Moderately elevated carboxyhemoglobin (COHb > 2%) vs. COHb ≤ 2% was evaluated on Need for antiarrhythmic treatment during the first 6 hours after admission (p=0.003). Moderately elevated carboxyhemoglobin (>2%) in patients with acute ischemic heart disease significantly increased the need for early antiarrhythmic treatment (p=0.003).